- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04261777
Ferumoxtran-10-enhanced MRI in Prostate Cancer Patients
A Confirmatory, Prospective, Open-label, Single-arm, Reader-blinded Multi-centre Phase 3 Study to Assess the Diagnostic Accuracy of Ferumoxtran-10-enhanced Magnetic Resonance Imaging (MRI) and Unenhanced MRI in Reference to Histopathology in Newly-diagnosed Prostate Cancer (PCA) Patients, Scheduled for Radical Prostatectomy (RP) With Extended Pelvic Lymph Node Dissection (ePLND).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Potential patients for this study will be recruited by up to 10 centres specialised in prostate cancer. Study sites will be interdisciplinary, consisting of a uro-oncology sub-site, and a radiology sub-site with high-quality MRI, surgery and pathology. Study visits will be typically conducted at the recruiting sub-site, or as institutionally appropriate. Treatment visits for patients will be performed in the collaborating sub-site. Patients will be invited for study participation by the investigators in the context of specialised clinics. Interested patients will be provided with an information sheet and will undergo a detailed informed consent procedure prior to any study procedures. Recruitment will be continued until a sufficient number of patients have undergone Ferrotran® imaging and histopathological evaluation.
To compensate for an expected drop-out rate of 15% to 20%, recruitment will only be stopped as soon as at least 69 evaluable positive (patients positive) and at least 104 evaluable negative (patients negative) patients are available for analysis.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Jürgen Feuerstein, Dr.
- Phone Number: +31 24 303 10 90
- Email: info@splmed.com
Study Contact Backup
- Name: Volker Meyer, Dr.
- Phone Number: +49 351 21 444 0
- Email: info@abx-cro.com
Study Locations
-
-
-
Gent, Belgium, 9000
- Recruiting
- Universitair Ziekenhuis Ghent
-
-
-
-
-
Berlin, Germany, 10967
- Recruiting
- Vivantes Klinikum Am Urban
-
Berlin, Germany, 10117
- Recruiting
- Charité - Universitätsklinikum Berlin
-
Bonn, Germany, 53127
- Recruiting
- Universitätsklinikum Bonn
-
Cologne, Germany, 50937
- Recruiting
- Universitätsklinikum Köln
-
Dresden, Germany, 01307
- Recruiting
- Universitätsklinikum Carl Gustav Carus
-
Düsseldorf, Germany, 40225
- Recruiting
- Universitätsklinikum Düsseldorf
-
Essen, Germany, 45147
- Recruiting
- Universitätsklinikum Essen
-
Leipzig, Germany, 04103
- Recruiting
- Universitätsklinikum Leipzig
-
Lübeck, Germany, 23538
- Recruiting
- Universitätsklinikum Schleswig-Holstein Lübeck
-
Mannheim, Germany, 68167
- Not yet recruiting
- Universitätsmedizin Mannheim Medizinische Fakultät Mannheim der Universität Heidelberg
-
-
-
-
-
Amsterdam, Netherlands, 1006
- Recruiting
- Nederlands Kanker Instituut Antoni van Leeuwenhoek
-
Nijmegen, Netherlands, 6525
- Recruiting
- Radboud University Medical Center
-
Nijmegen, Netherlands, 6532
- Recruiting
- Canisius-Wilhelmina Ziekenhuis Nijmegen
-
-
-
-
-
Bern, Switzerland, 3010
- Recruiting
- Inselspital-Universitatsspital Bern
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Voluntarily given and written informed consent.
- Male ≥18 years of age.
- Histologically newly-confirmed adenocarcinoma of the prostate.
Medium to high risk for lymph node metastasis, defined by either:
- PSA ≥10 ng/mL or
- Gleason-Score ≥7 or
- Stage cT2b or cT2c or T3 or T4
- Patients scheduled for radical prostatectomy (RP) with extended lymph node dissection (ePLND) between Day 7 and Day 42 after Ferrotran®-enhanced MRI.
- Consent to practice contraception until end of study, including female partners of childbearing potential. Effective contraceptive measures include hormonal oral, injected or implanted female contraceptives, male condom, vaginal diaphragm, cervical cap, intrauterine device.
Exclusion Criteria:
- Any contraindication to MRI, as per standard criteria.
- Any radiation therapy or systemic antiproliferative (chemo-, immuno, or hormonal) therapy for prostate cancer (Lupron, Taxotere, Casodex, Eulexin, Zoladex, etc.) prior to screening and until after post-surgery FUP MRI.
- Known hypersensitivity to Ferrotran® or its components such as dextran.
- Known hypersensitivity to other parenteral iron products.
- Acute allergy, including drug allergies and allergic asthma.
- Evidence of iron overload or disturbances in the utilisation of iron (e.g., haemochromatosis, haemosiderosis, chronic haemolytic anaemia with frequent blood transfusions).
- Presence of liver dysfunction.
- Any other investigational medicinal product within 30 days prior to receiving study medication until end of study visit.
- Simultaneous participation in any other clinical trial.
- Abnormal safety laboratory values at screening or baseline that are assessed by the principal investigator as clinically relevant.
- Patients not able to declare meaningful informed consent on their own (e.g. with legal guardian for mental disorders), or other vulnerable patients (e.g. under arrest).
- Patients with acute SARS-CoV-2 infection
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SPL-01-001
|
Ferrotran® in a dose of 0.13 mL/kg body weight of the reconstituted freeze-dried preparation (i.e. 2.6 mgFe/kg body weight). The recommended dose should be diluted in 100 mL of NaCl 9 mg/mL (0.9%) solution for injection/infusion prior to administration via the infusion filter as a slow intravenous infusion over 30 minutes (at a maximum rate of 4 mL/min). Ferrotran® will be administered once to each patient. Histologically confirmed diagnosis and pre-operative staging are performed prior to the study as part of standard care. Surgery (RP with ePLND) and sampling of tissue specimens is performed after the Ferrotran®-enhanced MRI as part of standard care.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Lymph node metastases will be detected by MRI scan (Ferumoxtran-10-enhanced and unenhanced).
Time Frame: up to day 42
|
True positive fraction and false positive fraction of identified tumour tissue in pelvic lymph nodes will be analysed by histopathology as established reference method.
|
up to day 42
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number and regions of lymph node metastases present in the follow-up MRI in comparison to pre-surgery MRI (unenhanced and Ferrotran®-enhanced).
Time Frame: up to day 105
|
up to day 105
|
Frequency of occurrence and severity of abnormal findings in safety investigations (physical examination, vital signs, 12-lead ECG, clinical laboratory, concomitant medication, adverse events)
Time Frame: day 0 - day 105
|
day 0 - day 105
|
Percentage of subjects for whom the patient management plan would be changed based on the Ferrotran®-enhanced MRI.
Time Frame: up to day 105
|
up to day 105
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Jelle Barentsz, MD, Radboud University Medical Center
Publications and helpful links
General Publications
- D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998 Sep 16;280(11):969-74. doi: 10.1001/jama.280.11.969.
- Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, de la Rosette J, Weissleder R. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med. 2003 Jun 19;348(25):2491-9. doi: 10.1056/NEJMoa022749. Erratum In: N Engl J Med. 2003 Sep 4;349(10):1010.
- Heesakkers RA, Hovels AM, Jager GJ, van den Bosch HC, Witjes JA, Raat HP, Severens JL, Adang EM, van der Kaa CH, Futterer JJ, Barentsz J. MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. Lancet Oncol. 2008 Sep;9(9):850-6. doi: 10.1016/S1470-2045(08)70203-1. Epub 2008 Aug 15.
- Heesakkers RA, Jager GJ, Hovels AM, de Hoop B, van den Bosch HC, Raat F, Witjes JA, Mulders PF, van der Kaa CH, Barentsz JO. Prostate cancer: detection of lymph node metastases outside the routine surgical area with ferumoxtran-10-enhanced MR imaging. Radiology. 2009 May;251(2):408-14. doi: 10.1148/radiol.2512071018.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SPL-01-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Barbara Ann Karmanos Cancer InstituteGenentech, Inc.CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
Clinical Trials on Ferrotran® (Ferumoxtran-10)
-
Radboud University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentUnknownProstatic Neoplasms | Lymphatic MetastasisNetherlands
-
OHSU Knight Cancer InstituteNational Institute of Neurological Disorders and Stroke (NINDS); National Institutes...TerminatedBrain NeoplasmsUnited States
-
Radboud University Medical CenterUnknown
-
Virginia Commonwealth UniversityNational Cancer Institute (NCI)Completed
-
University Health Network, TorontoPrincess Margaret Hospital, CanadaCompletedUterine Neoplasms | Prostatic Neoplasms | Cervix Neoplasms | Bladder NeoplasmsCanada
-
M.D. Anderson Cancer CenterTerminatedProstate Cancer | Bladder Cancer | Genitourinary CancerUnited States
-
Radboud University Medical CenterAstellas Pharma Inc; Catharina Ziekenhuis Eindhoven; Canisius-Wilhelmina HospitalUnknownProstate Cancer | Lymph Node MetastasesNetherlands
-
Mahidol UniversityPacific Health FoundationCompleted
-
Actinogen MedicalAvance ClinicalCompletedMild Cognitive Impairment | Alzheimer's DiseaseAustralia
-
University of OxfordNational Institute of Allergy and Infectious Diseases (NIAID); Wellcome TrustCompletedEbola | Ebola ZaireUnited Kingdom